Qiagen NV announced proposals for changes in the membership of the Supervisory Board that will be put forward for approval by shareholders at the next Annual General Meeting scheduled for June 26, 2013. The proposals for the composition of the Supervisory Board, who are elected to one-year terms, were made by the Selection and Appointment Committee and recommended for shareholder approval by a Joint Meeting of the Supervisory Board and the Managing Board. Two new members have been proposed for election to the Supervisory Board: Stéphane Bancel, 40, is President and Founding CEO of Moderna Therapeutics Inc., a start-up biotechnology company based in Cambridge, Massachusetts, that is advancing multiple drug development programs involving messenger RNA therapeutics.

Lawrence A. Rosen, 55, is a member of the Board of Management and Chief Financial Officer of Deutsche Post DHL. In this position, which he has held since September 2009, Rosen is in charge of Controlling, Corporate Accounting and Reporting, Investor Relations, Corporate Finance, Corporate Internal Audit and Security, Taxes, as well as the Group's Global Business Services. Two members of the Supervisory Board - Mr. Erik Hornnaess and Mr. Heino von Prondzynski - have decided not to stand for re-election.

Mr. Hornnaess has been a member of the Supervisory Board since 1998 and currently serves as Deputy Chairman of the Supervisory Board, Chairman of the Compensation Committee, Member of the Audit Committee and the Selection and Appointment Committee. Mr. von Prondzynski has been a member of the Supervisory Board since 2007 and also served as a Member of the Audit Committee.